Adjuvant sequential chemoradiation therapy in high-risk endometrial cancer: Results of a prospective, multicenter phase-II study of the NOGGO (North-Eastern German Society of Gynaecological Oncology)

Cancer Chemotherapy and Pharmacology

Volumn 72, Issue 5, 2013, Pages 975-983

  Mustea, A ^a   Koensgen, D ^a   Belau, A ^a   Sehouli, J ^b   Lichtenegger, W ^b   Schneidewind, L ^a   Sommer, H ^c   Markmann, S ^d   Scharf, J P ^e   Ehmke, M ^e   Ledwon, P ^f   Braicu, I ^b   Zygmunt, M ^a   Koehler, G ^a  

^a UNIVERSITY MEDICINE GREIFSWALD   (Germany)

^b HUMBOLDT UNIVERSITY   (Germany)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^d ROSTOCK UNIVERSITY MEDICAL CENTER   (Germany)

^e SANA KLINIKUM OFFENBACH   (Germany)

^f Klinikum Brandenburg   (Germany)

Author keywords

Adjuvant chemoradiation; High risk endometrial cancer; Quality of life; Toxicity

Indexed keywords

CARBOPLATIN; DEXAMETHASONE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PACLITAXEL; SEROTONIN 3 ANTAGONIST; ANTINEOPLASTIC AGENT;

ADJUVANT CHEMORADIOTHERAPY; ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; BLOOD TOXICITY; BLOOD TRANSFUSION; BONE MARROW TOXICITY; BRACHYTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DRUG HYPERSENSITIVITY; DRUG TOLERABILITY; ENDOMETRIUM CANCER; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HIGH RISK PATIENT; HUMAN; INFECTION; INSOMNIA; LEUKOPENIA; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUROLOGIC DISEASE; OUTCOME ASSESSMENT; PAIN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RADIATION INDUCED EMESIS; RADIATION INJURY; SCORING SYSTEM; SURVIVAL TIME; THROMBOCYTOPENIA; CANCER STAGING; CLINICAL TRIAL; DRUG EFFECTS; ENDOMETRIAL NEOPLASMS; ENDOMETRIUM; FEASIBILITY STUDY; GERMANY; HEMATOLOGIC DISEASES; INCIDENCE; MIDDLE AGED; PATHOLOGY; PROGNOSIS; RADIATION RESPONSE; SURVIVAL;

AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRACHYTHERAPY; CARBOPLATIN; CHEMORADIOTHERAPY, ADJUVANT; ENDOMETRIAL NEOPLASMS; ENDOMETRIUM; FEASIBILITY STUDIES; FEMALE; FOLLOW-UP STUDIES; GERMANY; HEMATOLOGIC DISEASES; HUMANS; INCIDENCE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; PACLITAXEL; PROGNOSIS; QUALITY OF LIFE; SURVIVAL ANALYSIS;

EID: 84887146128     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-013-2276-9     Document Type: Article

References (49)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN. Int J Cancer 127(12):2893-2917
2. Creasman WT, Odicino F, Maisonneuve P, Quinn MA, Beller U, Benedett JL, Heintz AP, Ngan HY, Pecorelli S (2006) Carcinoma of the corpus uteri. FIGO 26th annual report on the results of treatment in gynecological cancer. Int J Gynaecol Obstet 95(Suppl 1): 105-143
3. Randall ME, Filiaci VL, Muss H, Spirtos NM, Mannel RS, Fowler J, Thigpen JT, Benda JA (2006) Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol 24:36-44 (Pubitemid 46630491)
4. Maggi R, Lissoni A, Spina F, Melpignano M, Zola P, Favalli G, Colombo A, Fossati R (2006) Adjuvant chemotherapy vs. radiotherapy in high-risk endometrial carcinoma: results of a randomised trial. Br J Cancer 95:266-271 (Pubitemid 44187586)
5. Susumu N, Sagae S, Udagawa Y, Niwa K, Kuramoto H, Satoh S, Kudo R, Japanese Gynecologic Oncology Group (2008) Randomized phase III trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate- and high-risk endometrial cancer: a Japanese Gynecologic Oncology Group study. Gynecol Oncol 108:226-233 (Pubitemid 350299451)
6. Aalders J, Abeler V, Kolstad P, Onsrud M (1980) Postoperative external irradiation and prognostic parameters in stage I endometrial carcinoma: clinical and histopathologic study of 540 patients. Obstet Gynecol 56(4):419-427 (Pubitemid 10018299)
7. Keys HM, Roberts JA, Brunetto VL, Zaino RJ, Spirtos NM, Bloss JD, Pearlman A, Maiman MA, Bell JG, Gynecologic Oncology Group (2004) A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 92(3):744-751 (Pubitemid 38251372)
8. Creutzberg CL, van Putten WL, Koper PC, Lybeert ML, Jobsen JJ, Wárlám-Rodenhuis CC, De Winter KA, Lutgens LC, van den Bergh AC, van de Steen-Banasik E, Beerman H, van Lent M (2000) Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma. Lancet 355(9213):1404-1411 (Pubitemid 30215963)
9. Creutzberg CL, Nout RA, Lybeert ML, Wárlám-Rodenhuis CC, Jobsen JJ, Mens JW, Lutgens LC, Pras E, van de Poll-Franse LV, van Putten WL, PORTEC study group (2011) Fifteen-year radiotherapy outcomes of the randomized PORTEC-1 trial for endometrial carcinoma. Int J Radiat Oncol Biol Phys 81(4):631-638
10. Blake P, Swart AM, Orton J, Kichener H, Whelan T, Lukka H, Eisenhauer E, Bacon M, Tu D, Parman MK, Amos C, Murray C, Qian W, ASTEC/EN.5 Study Group (2009) Adjuvant external beam radiotherapy in the treatment of endometrial cancer (MRC ASTEC and NCIC CTG EN.5 randomised trials): pooled trial results, systematic review, and meta-analysis. Lancet 373(9658):137-146
11. Nout RA, Putter H, Jürgenliemk-Schulz IM, Jobsen JJ, Lutgens LC, van der Steen-Banasik EM, Mens JW, Slot A, Stenfert Kroese MC, van Bunningen BN, Smit VT, Nijman HW, van den Tol PP, Creutzberg CL (2009) Quality of life after pelvic radiotherapy or vaginal brachytherapy for endometrial cancer: first results of the randomized PORTEC-2 trial. J Clin Oncol 27(21):3547-3556
12. Nout RA, Smit VT, Putter H, Jürgenliemk-Schulz IM, Jobsen JJ, Lutgens LC, van der Steen-Banasik EM, Mens JW, Slot A, Kroese MC, van Bunningen BN, Ansink AC, van Putten WL, Creutzberg CL, PORTEC Study Group (2010) Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial. Lancet 375(9717):816-823
13. Aapro MS, van Wijk FH, Bolis G, European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group et al (2003) Doxorubicin versus doxorubicin and cisplatin in endometrial carcinoma: definitive results of a randomised study (55872) by the EORTC Gynaecological Cancer Group. Ann Oncol 14:441-448 (Pubitemid 36367423)
14. Thigpen JT, Brady MF, Homesley HD, Malfetano J, DuBeshter B, Burger RA, Liao S (2004) Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a gynecologic oncology group study. J Clin Oncol 22:3902-3908 (Pubitemid 41079871)
15. Fleming GF, Brunetto VL, Cella D, Look KY, Reid GC, Munkarah AR, Kline R, Burger RA, Goodman A, Burks RT (2004) Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol 22:2159-2166 (Pubitemid 41095150)
16. Mazgani M, Le N, Hoskins PJ (2008) British Columbia Cancer Agency Reuse of carboplatin and paclitaxel in patients with relapsed endometrial cancer - the British Columbia Cancer Agency experience. Gynecol Oncol 111:474-477
17. Pectasides D, Xiros N, Papaxoinis G, Pectasides E, Sykiotis C, Koumarianou A, Psyrri A, Gaglia A, Kassanos D, Gouveris P, Panayiotidis J, Fountzilas G, Economopoulos T (2008) Carboplatin and paclitaxel in advanced or metastatic endometrial cancer. Gynecol Oncol 109:250-254
18. Sorbe B, Andersson H, Boman K, Rosenberg P, Kalling M (2008) Treatment of primary advanced and recurrent endometrial carcinoma with a combination of carboplatin and paclitaxel-long-term follow-up. Int J Gynecol Cancer 18:803-808 (Pubitemid 352020182)
19. Vandenput I, Vergote I, Leunen K, Berteloot P, Neven P, Amant F (2009) Leuven dose-dense paclitaxel/carboplatin regimen in patients with primary advanced or recurrent endometrial carcinoma. Int J Gynecol Cancer 19:1147-1151
20. Morrow CP, Bundy BN, Homesley HD, Creasman WT, Hornback NB, Kurman R, Thigpen JT (1990) Doxorubicin as an adjuvant following surgery and radiation therapy in patients with high-risk endometrial carcinoma, stage I and occult stage II: a Gynecologic Oncology Group Study. Gynecol Oncol 36:166-171 (Pubitemid 20061279)
21. Sood BM, Timmins PF, Gorla GR, Garg M, Anderson PS, Vikram B, Goldberg GL (2002) Concomitant cisplatin and extended field radiation therapy in patients with cervical and endometrial cancer. Int J Gynecol Cancer 12:459-464
22. Mangili G, De Marzi P, Beatrice S, Rabaiotti E, Viganò R, Frigerio L, Gentile C, Fazio F (2006) Paclitaxel and concomitant radiotherapy in high-risk endometrial cancer patients: preliminary findings. BMC Cancer 6:198 (Pubitemid 44322239)
23. Greven K, Winter K, Underhill K, Fontenesci J, Cooper J, Burke T, Radiation Therapy Oncology Group (2006) Final analysis of RTOG 9708: adjuvant postoperative irradiation combined with cisplatin/paclitaxel chemotherapy following surgery for patients with high-risk endometrial cancer. Gynecol Oncol 103:155-159 (Pubitemid 44374683)
24. Foad I, Sharawy I, Mostafa E, Margergis M, Hussein T (2007) Concurrent cisplatin/radiation followed by adjuvant cisplatin/paclitaxel in treatment of patients with stage IB grade 3, IC and IIA endometrial carcinoma. J Egypt Natl Cancer Inst 19:163-169
25. Alektiar KM, Makker V, Abu-Rustum NR, Soslow RA, Chi DS, Barakat RR, Aghajanian CA (2009) Concurrent carboplatin/paclitaxel and intravaginal radiation in surgical stage I-II serous endometrial cancer. Gynecol Oncol 112:142-145
26. Bruzzone M, Miglietta L, Franzone P, Gadducci A, Boccardo F (2004) Combined treatment with chemotherapy and radiotherapy in high-risk FIGO stage III-IV endometrial cancer patients. Gynecol Oncol 93(2):345-352 (Pubitemid 38507600)
27. Kuopalla T, Mäenpää J, Tomas E, Puistola U, Salmi T, Grenman S, Lehtovirta P, Fors M, Luukkaala T, Sipilä P (2008) Surgically staged high-risk endometrial cancer: randomized study of adjuvant radiotherapy alone vs. sequential chemoradiotherapy. Gynecol Oncol 110:190-195
28. Gehrig PA, Morris DE, Van Le L (2004) Uterine serous carcinoma: a comparison of therapy for advanced-stage disease. Int J Gynecol Cancer 14(3):515-520 (Pubitemid 38747433)
29. Sehouli J, Koensgen D, Oskay-Ozcelik G, Mustea A (2008) New aspects of adjuvant therapy in endometrial cancer: current standards and future directions. Crit Rev Oncol Hematol 67(3):204-212
30. Greven KM, Randall M, Fanning J, Bahktar M, Duray P, Peters A, Curran WJ Jr (1990) Patterns of failure in patients with stage I, grade 3 carcinoma of the endometrium. Int J Radiat Oncol Biol Phys 19:529-534 (Pubitemid 20324243)
31. Grigsby PW, Perez CA, Camel HM, Kao MS, Galakatos AE (1985) Stage II carcinoma of the endometrium: results of therapy and prognostic factors. Int J Radiat Oncol Biol Phys 11:1915-1923 (Pubitemid 16195119)
32. Hogberg T, Signorelli M, de Oliveira CF et al (2010) Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer-results from two randomised studies. Eur J Cancer 46(13):2422-2431
33. Soper J, Reisinger S, Ashbury R, Jones E, Clarke-Pearson DL (2004) Feasibility study of concurrent weekly cisplatin and whole abdominopelvic irradiation followed by doxorubicin/cisplatin chemotherapy for advanced stage endometrial cancer: a Gynecologic Oncology Group trial. Gynecol Oncol 95:95-100 (Pubitemid 39286283)
34. Fowler JM, Brady WE, Grigsby PW, Cohn DE, Mannel RS, Rader JS (2009) Sequential chemotherapy and irradiation in advanced stage endometrial cancer: A Gynecologic Oncology Group phase I trial of doxorubicin-cisplatin followed by whole abdomen irradiation. Gynecol Oncol 112(3):553-557
35. Secord AA, Havrilesky LJ, Carney ME, Soper JT, Clarke-Pearson DL, Rodriguez GC, Berchuck A (2007) Weekly low-dose paclitaxel and carboplatin in the treatment of advanced or recurrent cervical and endometrial cancer. Int J Clin Oncol 12:31-36 (Pubitemid 46472550)
36. Hoskins PJ, Swenerton KD, Pike JA, Wong F, Lim P, Acquino-Parsons C, Lee N (2001) Paclitaxel and carboplatin, alone or with irradiation, in advanced or recurrent endometrial cancer: a phase II study. J Clin Oncol 19:4048-4053 (Pubitemid 32976691)
37. Hidaka T, Nakamura T, Shima T, Yuki H, Saito S (2006) Paclitaxel/carboplatin versus cyclophosphamide/adriamycin/cisplatin as postoperative adjuvant chemotherapy for advanced endometrial adenocarcinoma. J Obstet Gynaecol Res 32:330-337 (Pubitemid 43800427)
38. Sovak M, Hensley M, Dupont J, Ishill N, Alektiar KM, Abu-Rustum N, Barakat R, Chi DS, Sabbatini P, Spriggs DR, Aghajanian C (2006) Paclitaxel and carboplatin in the adjuvant treatment of patients with high-risk stage III and IV endometrial cancer: a retrospective study. Gynecol Oncol 03:451-457 (Pubitemid 44740097)
39. Akram T, Maseelall P, Fanning J (2005) Carboplatin and paclitaxel for the treatment of advanced or recurrent endometrial cancer. Am J Obstet Gynecol 92:1365-1367
40. Miller D, Filiaci V, Fleming G, Mannel R, Cohn D, Matsumoto T et al (2012) Late-breaking Abstract 1: randomized phase III noninferiority trial of first line chemotherapy for metastatic or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study. Gynecol Oncol 125(3):771
41. Lupe K, Kwon J, D'Souza D, Gawlik C, Stitt L, Whiston F, Nascu P, Wong E, Carey MS (2007) Adjuvant paclitaxel and carboplatin chemotherapy with involved field radiation in advanced endometrial cancer: a sequential approach. Int J Radiat Oncol Biol Phys 67(1):110-116 (Pubitemid 44959483)
42. Duska LR, Berkowitz R, Matulonis U, Muto M, Goodman A, McIntyre JF, Klein A, Atkinson T, Seiden MV, Campos S (2005) A pilot trial of TAC (paclitaxel, doxorubicin, and carboplatin) chemotherapy with filgastrim (r-metHuG-CSF) support followed by radiotherapy in patients with "high-risk" endometrial cancer. Gynecol Oncol 96:198-203 (Pubitemid 39612437)
43. Frigerio L, Mangili G, Aletti G, Carnelli M, Garavaglia E, Beatrice S, Ferrari A (2001) Concomitant radiotherapy and paclitaxel for high-risk endometrial cancer: first feasibility study. Gynecol Oncol 81(1):53-57 (Pubitemid 32368077)
44. Abaid LN, Rettenmaier MA, Brown JV 3rd, Micha JP, Mendivil AA, Wabe MA, Goldstein BH (2012) Sequential chemotherapy and radiotherapy as sandwich therapy for the treatment of high risk endometrial cancer. J Gynecol Oncol 23(1):22-27
45. van de Poll-Franse LV, Mols F, Essink-Bot ML, Haartsen JE, Vingerhoets AJ, Lybeert ML, van den Berg HA, Coebergh JW (2007) Impact of external-beam adjuvant radiotherapy on health-related quality of life for long-term survivors of endometrial adenocarcinoma: a population-based study. Int J Radiat Oncol Biol Phys 69:125-132 (Pubitemid 47247508)
46. Bradley S, Rose S, Lutgendorf S, Costanzo E, Anderson B (2006) Quality of life and mental health in cervical and endometrial cancer survivors. Gynecol Oncol 100:479-486 (Pubitemid 43246862)
47. Bye A, Trope C, Loge JH, Hjermstad M, Kaasa S (2000) Health-related quality of life and occurrence of intestinal side effects after pelvic radiotherapy: evaluation of longterm effects of diagnosis and treatment. Acta Oncol 39:173-180 (Pubitemid 30316884)
48. Fader AN, Drake RD, O'Malley DM, Gibbons HE, Huh WK, Havrilesky LJ, Gehrig PA, Tuller E, Axtell AE, Zanotti KM, Uterine Papillary Serous Carcinoma (UPSC) Consortium Cancer (2009) Platinum/taxane-based chemotherapy with or without radiation therapy favorably impacts survival outcomes in stage I uterine papillary serous carcinoma. Cancer 115(10):2119-2127
49. Lupe K, D'Souza DP, Kwon JS, Radwan JS, Harle IA, Hammond JA, Carey MS (2009) Adjuvant carboplatin and paclitaxel chemotherapy interposed with involved field radiation for advanced endometrial cancer. Gynecol Oncol 114(1):94-98